Altimmune Stock

Altimmune ROA

The Return on Assets (ROA) of Altimmune (ALT) as of Jul 24, 2026 is -68.24 %. In the previous year, Return on Assets (ROA) was -41.99 % — a change of 62.51% (lower).

ROA

-68.24 %

YoY

62.51%

Last updated:

In 2026, Altimmune's return on assets (ROA) was -68.24 %, a 62.51% increase from the -41.99 % ROA in the previous year.

Access this data via the Eulerpool API

Altimmune Stock analysis

What does Altimmune do? Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune is one of the most popular companies on Eulerpool.

ROA Details

Understanding Altimmune's Return on Assets (ROA)

Altimmune's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Altimmune's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Altimmune's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Altimmune’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Altimmune stock

Return on Assets (ROA) of Altimmune is -68.24 % in 2026.

Access this data via the Eulerpool API

Profitability — Altimmune

All Key Metrics — Altimmune